Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version)

Masatoshi Kudo, Shouji Kubo, Kenichi Takayasu, Michiie Sakamoto, Masatoshi Tanaka, Iwao Ikai, Junji Furuse, Kenji Nakamura, Masatoshi Makuuchi

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

The World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST) are inappropriate to assess the direct effects of treatment on the hepatocellular carcinoma (HCC) by locoreginal therapies such as radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE). Therefore, establishment of response evaluation criteria solely devoted for HCC is needed urgently in the clinical practice as well as in the clinical trials of HCC treatment, such as molecular targeted therapies, which cause necrosis of the tumor. Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2009 by Liver Cancer Study Group of Japan based on the 2004 version of RECICL, which was commonly used in Japan. Major revised points of the RECICL 2009 is to provide TE4a (Complete response with enough ablative margin) and TE4b (complete response without enough ablative margin) for local ablation therapy. Second revised point is that setting the timing at which the overall treatment effects are assessed. Third point is that emergence of new lesion in the liver is regarded as progressive disease, different from 2004 version. Finally, 3 tumor markers including alpha-fetoprotein (AFP) and AFP-L3 and des-gamma-carboxy protein (DCP) were also added for the overall treatment response. We hope this new treatment response criteria, RECICL, proposed by Liver Cancer Study Group of Japan will benefit the HCC treatment response evaluation in the setting of the daily clinical practice and clinical trials as well not only in Japan, but also internationally.

Original languageEnglish
Pages (from-to)686-692
Number of pages7
JournalHepatology Research
Volume40
Issue number7
DOIs
Publication statusPublished - 2010 Jul
Externally publishedYes

Fingerprint

Liver Neoplasms
Japan
Hepatocellular Carcinoma
alpha-Fetoproteins
Therapeutics
Clinical Trials
Molecular Targeted Therapy
Tumor Biomarkers
Necrosis
Liver
Neoplasms

Keywords

  • Hepatocellular carcinoma
  • Liver Cancer
  • Liver Cancer Study Group of Japan
  • RECIST
  • Response Evaluation Criteria
  • WHO criteria

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). / Kudo, Masatoshi; Kubo, Shouji; Takayasu, Kenichi; Sakamoto, Michiie; Tanaka, Masatoshi; Ikai, Iwao; Furuse, Junji; Nakamura, Kenji; Makuuchi, Masatoshi.

In: Hepatology Research, Vol. 40, No. 7, 07.2010, p. 686-692.

Research output: Contribution to journalArticle

Kudo, Masatoshi ; Kubo, Shouji ; Takayasu, Kenichi ; Sakamoto, Michiie ; Tanaka, Masatoshi ; Ikai, Iwao ; Furuse, Junji ; Nakamura, Kenji ; Makuuchi, Masatoshi. / Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). In: Hepatology Research. 2010 ; Vol. 40, No. 7. pp. 686-692.
@article{c984db46988b4231a9587f4f52b414d2,
title = "Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version)",
abstract = "The World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST) are inappropriate to assess the direct effects of treatment on the hepatocellular carcinoma (HCC) by locoreginal therapies such as radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE). Therefore, establishment of response evaluation criteria solely devoted for HCC is needed urgently in the clinical practice as well as in the clinical trials of HCC treatment, such as molecular targeted therapies, which cause necrosis of the tumor. Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2009 by Liver Cancer Study Group of Japan based on the 2004 version of RECICL, which was commonly used in Japan. Major revised points of the RECICL 2009 is to provide TE4a (Complete response with enough ablative margin) and TE4b (complete response without enough ablative margin) for local ablation therapy. Second revised point is that setting the timing at which the overall treatment effects are assessed. Third point is that emergence of new lesion in the liver is regarded as progressive disease, different from 2004 version. Finally, 3 tumor markers including alpha-fetoprotein (AFP) and AFP-L3 and des-gamma-carboxy protein (DCP) were also added for the overall treatment response. We hope this new treatment response criteria, RECICL, proposed by Liver Cancer Study Group of Japan will benefit the HCC treatment response evaluation in the setting of the daily clinical practice and clinical trials as well not only in Japan, but also internationally.",
keywords = "Hepatocellular carcinoma, Liver Cancer, Liver Cancer Study Group of Japan, RECIST, Response Evaluation Criteria, WHO criteria",
author = "Masatoshi Kudo and Shouji Kubo and Kenichi Takayasu and Michiie Sakamoto and Masatoshi Tanaka and Iwao Ikai and Junji Furuse and Kenji Nakamura and Masatoshi Makuuchi",
year = "2010",
month = "7",
doi = "10.1111/j.1872-034X.2010.00674.x",
language = "English",
volume = "40",
pages = "686--692",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "7",

}

TY - JOUR

T1 - Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version)

AU - Kudo, Masatoshi

AU - Kubo, Shouji

AU - Takayasu, Kenichi

AU - Sakamoto, Michiie

AU - Tanaka, Masatoshi

AU - Ikai, Iwao

AU - Furuse, Junji

AU - Nakamura, Kenji

AU - Makuuchi, Masatoshi

PY - 2010/7

Y1 - 2010/7

N2 - The World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST) are inappropriate to assess the direct effects of treatment on the hepatocellular carcinoma (HCC) by locoreginal therapies such as radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE). Therefore, establishment of response evaluation criteria solely devoted for HCC is needed urgently in the clinical practice as well as in the clinical trials of HCC treatment, such as molecular targeted therapies, which cause necrosis of the tumor. Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2009 by Liver Cancer Study Group of Japan based on the 2004 version of RECICL, which was commonly used in Japan. Major revised points of the RECICL 2009 is to provide TE4a (Complete response with enough ablative margin) and TE4b (complete response without enough ablative margin) for local ablation therapy. Second revised point is that setting the timing at which the overall treatment effects are assessed. Third point is that emergence of new lesion in the liver is regarded as progressive disease, different from 2004 version. Finally, 3 tumor markers including alpha-fetoprotein (AFP) and AFP-L3 and des-gamma-carboxy protein (DCP) were also added for the overall treatment response. We hope this new treatment response criteria, RECICL, proposed by Liver Cancer Study Group of Japan will benefit the HCC treatment response evaluation in the setting of the daily clinical practice and clinical trials as well not only in Japan, but also internationally.

AB - The World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST) are inappropriate to assess the direct effects of treatment on the hepatocellular carcinoma (HCC) by locoreginal therapies such as radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE). Therefore, establishment of response evaluation criteria solely devoted for HCC is needed urgently in the clinical practice as well as in the clinical trials of HCC treatment, such as molecular targeted therapies, which cause necrosis of the tumor. Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2009 by Liver Cancer Study Group of Japan based on the 2004 version of RECICL, which was commonly used in Japan. Major revised points of the RECICL 2009 is to provide TE4a (Complete response with enough ablative margin) and TE4b (complete response without enough ablative margin) for local ablation therapy. Second revised point is that setting the timing at which the overall treatment effects are assessed. Third point is that emergence of new lesion in the liver is regarded as progressive disease, different from 2004 version. Finally, 3 tumor markers including alpha-fetoprotein (AFP) and AFP-L3 and des-gamma-carboxy protein (DCP) were also added for the overall treatment response. We hope this new treatment response criteria, RECICL, proposed by Liver Cancer Study Group of Japan will benefit the HCC treatment response evaluation in the setting of the daily clinical practice and clinical trials as well not only in Japan, but also internationally.

KW - Hepatocellular carcinoma

KW - Liver Cancer

KW - Liver Cancer Study Group of Japan

KW - RECIST

KW - Response Evaluation Criteria

KW - WHO criteria

UR - http://www.scopus.com/inward/record.url?scp=77954528010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954528010&partnerID=8YFLogxK

U2 - 10.1111/j.1872-034X.2010.00674.x

DO - 10.1111/j.1872-034X.2010.00674.x

M3 - Article

VL - 40

SP - 686

EP - 692

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 7

ER -